
    
      Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group
      B: naloxone max 16 mg/per day. Study duration 8 weeks. No supportive therapy, but brief
      self-help booklet. Primary outcomes: adverse events, adherence and drop out analysis.
      Secondary outcome: gambling expenditure.
    
  